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ABSTRACT
Fluoxetine is one of the most commonly prescribed medications for many behavioral and neurological
disorders. Fluoxetine acts primarily as an inhibitor of the serotonin reuptake transporter (SERT) to block
the removal of serotonin from the synaptic cleft, thereby enhancing serotonin signals. While the effects of
fluoxetine on behavior are firmly established, debate is ongoing whether inhibition of serotonin reuptake
is a sufficient explanation for its therapeutic action. Here, we provide evidence of two additional aspects of
fluoxetine action through genetic analyses in Caenorhabditis elegans. We show that fluoxetine treatment
and null mutation in the sole SERT gene mod-5 eliminate serotonin in specific neurons. These neurons do
not synthesize serotonin but import extracellular serotonin via MOD-5/SERT. Furthermore, we show that
fluoxetine acts independently of MOD-5/SERT to regulate discrete properties of acetylcholine (Ach),
gamma-aminobutyric acid (GABA), and glutamate neurotransmission in the locomotory circuit. We
identified that two G-protein–coupled 5-HT receptors, SER-7 and SER-5, antagonistically regulate the
effects of fluoxetine and that fluoxetine binds to SER-7. Epistatic analyses suggest that SER-7 and SER-5
act upstream of AMPA receptor GLR-1 signaling. Our work provides genetic evidence that fluoxetine may
influence neuronal functions and behavior by directly targeting serotonin receptors.
FLUOXETINE is a selective serotonin reuptakeinhibitor (SSRI) and has made a major impact
on the treatment of many behavioral disorders. The
empirical action of SSRIs is blocking the serotonin
reuptake transporter (SERT). SERT is localized in the
plasma membrane and transports extracellular seroto-
nin (5-HT) into the cytoplasm (Blakely et al. 1991;
Hoffman et al. 1991), this being the major mechanism
of terminating 5-HT signaling. Consequently, SSRIs are
thought to exert therapeutic effects by blocking SERT
from removal of 5-HT in the synaptic clef, thereby
increasing the level of 5-HT signals (Schatzberg and
Nemeroff 2004). However, several observations point
to additional actions of SSRIs on the 5-HT system and
neuronal functions. First, knockout of SERT in mouse
caused a marked reduction of 5-HT in the brain
(Bengel et al. 1998). Second, a variety of studies with
cultured mammalian cells and mouse brain slices
showed that SSRIs and tricyclic antidepressant agents
(TCAs) have high affinities to many 5-HT receptor
subtypes and act as agonists or antagonists depending
on particular receptors being tested (Ni and Miledi
1997; Kroeze and Roth 1998; Eisensamer et al. 2003).
Third, genetic analyses of the nematode Caenorhabditis
elegans in our laboratory and others showed that
fluoxetine and the TCA imipramine (Tofrani) could
influence behavior independent of SERT function
(Weinshenker et al. 1995; Ranganathan et al. 2001;
Dempsey et al. 2005). In this study, we carried out a
systematic survey of SSRIs treatment in C. elegans to gain
new insights into actions of SSRIs on the 5-HT system
and other neurotransmitter systems.
In both vertebrates and invertebrates, 5-HT functions
as a neuromodulator to either facilitate or inhibit
synaptic transmission of other neurotransmitters (Fink
and Gothert 2007). Modulation of synaptic activity by
5-HT signaling underscores the synaptic plasticity in-
volved in stress responses, learning, adaptation, and
memory (Kandel 2001; Zhang et al. 2005). The role
of 5-HT in C. elegans was initially identified through
pharmacological experiments showing that exogenous
5-HT can promptly induce changes in a variety of
behaviors, including feeding, egg laying, and locomo-
tion (Avery and Horvitz 1990; Weinshenker et al.
1995; Nurrish et al. 1999). The relevance of these
behaviors to endogenous 5-HT has since been validated
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through studies of mutants of 5-HT signaling. Impor-
tantly, multiple 5-HT receptors may function in distinct
cells synergistically or antagonistically to regulate a
specific behavior (Carnell et al. 2005; Dernovici
et al. 2007; Murakami and Murakami 2007; Hapiak
et al. 2009). In nearly all tested paradigms, fluoxetine
and imipramine induce behavioral changes similarly
to exogenous 5-HT (Weinshenker et al. 1995; Nurrish
et al. 1999), implying that fluoxetine regulates 5-HT
inputs to these neural circuits. However, the tryptophan
hydroxylase gene tph-1 is required for 5-HT biosynthesis
inC. elegans (Sze et al. 2000),mod-5 encodes its sole SERT
(Ranganathan et al. 2001), and yet fluoxetine could
stimulate egg laying and inhibit locomotion in mod-5
and tph-1mutants (Weinshenker et al. 1995; Choy and
Thomas 1999; Ranganathan et al. 2001; Dempsey et al.
2005). These findings provided a basis for further
investigation into genes and synaptic functions regu-
lated by 5-HT and the impact of fluoxetine on 5-HT
signaling.
Here we present genetic evidence of multifaceted ef-
fects of fluoxetine on the 5-HT system and its down-
stream targets in C. elegans. We show that fluoxetine
treatment and loss of MOD-5/SERT function do not
simply increase presynaptic 5-HT signals. Rather, they
may eliminate 5-HT in specific neurons. Furthermore,
fluoxetine acts independently of SERT to regulate
5-HT serotonin receptors and their downstream targets
involved in acetylcholine (ACh), gamma-aminobutyric
acid (GABA), and glutamate neurotransmission.
MATERIALS AND METHODS
Strains: The maintenance of C. elegans strains, nematode
growth media (NGM), and standard buffers (M9, S-basal,
and S-medium) used to handle worms have been described
(Brenner 1974). Wild type (WT) was the Bristol strain
N2. Mutant strains used were as follows: dop-6(ok2090),
cha-1(p1152), pha-1(e2123);mdIs18[Punc-17TGFP;pha-1(1)]
(AChTgfp) (from J. Rand, University of Oklahoma Health
Sciences Center, Oklahoma City, OK), eat-4(ad572), eat-
4(n2474), glr-1(n2461), KP987 lin-15B(n765) nuIs1 X[lin-
15(1); PV6 glr-1TGFP); mod-5(n3314), mod-5(n822) (from
R. Horvitz, Massachusetts Institute of Technology, Cambridge,
MA), mod-1(ok103), myo-3(st386);stEx30 [Pmyo-3TGFP;rol-
6(su1006)] (MYO-3TGFP), nrf-6 (sa525), ser-1(ok345), ser-3
(ok1995), ser-3 (ad1774), ser-3(ok2007), ser-4(ok512), ser-5(tm2654),
ser-5(tm2647), ser-7(tm1325), ser-7(tm1548), ser-7(tm1728), slo-
1(js379), slo-1(ky399), tag-24 (ok371), tom-1(ok285), tph-1(mg280),
unc-25(e156), unc-29(e193), unc-43(e408), unc-43(n498), unc-
49(e407), and EG1653 (lin-15(n765ts); oxIs22[pEK(lin-15 1);
UNC-49BTGFP] (from E. Jorgensen, University of Utah, Salt
Lake City, UT).
Constructions of ser-5(1) and ser-7(1) transgenes: The
constructs were generated by PCR, and purified PCR products
were used to generate transgenic worms. elt-2Tgfp, which is
expressed in the gut (Fukushige et al. 1999), was used as a
transgenic marker. ser-5(1) was a genomic fragment amplified
from the WT genome encompassing a 6305-bp 59-upstream
promoter sequence, exons/introns, anda1118-bp39-untranslated
region (UTR) of the ser-5 gene. ser-7(1) was a genomic fragment
containing a 1858-bp 59-upstream promoter sequence, exons/
introns, and a 174-bp 39-UTR of the ser-7 gene.
Indirect immunofluorescence histochemistry and
microscopy: Whole-mount staining of C. elegans with anti-
5-HT antibodies was performed as described previously (Sze
et al. 2002). To analyze the effect of fluoxetine and imipramine
on 5-HT immunoreactivity, the drugs were dissolved in water
and the solution was poured onto NGM plates to give the
final concentration of 0.4 mg/ml imipramine or 0.5 mg/ml
fluoxetine. The plates were dried under a hood for 2–3 hr
and used immediately. Well-fed mixed-staged worms were
incubated on the drug plates overnight and then fixed for
staining. The control animals were raised and stained in
parallel but without drug treatment. Stained animals were
viewed using an AxioImager Z1 microscope equipped with
proper filters and an Axiocam MR digital camera (Zeiss,
Northwood, NY).
Drug and behavioral assays: Sensitivity to fluoxetine and
other SSRIs was scored by calculating the percentage of
animals paralyzed after being incubated in a liquid medium
containing a drug. In all experiments except that described
in Figure 2, a and c, the assays were carried out in culture
media containing food. Food used in this assay was Escher-
ichia coli OP50. A single colony of the bacteria was inoculated
in 250 ml of 2xYT medium with shaking at 37 overnight.
The resulting bacteria were concentrated by centrifugation,
and the pellet was resuspended in 3 ml of S-basal. Worms
were washed off NGM plates with M9 and the number of
worms in the suspension was adjusted to 1000 worms/ml.
Drug assays were carried out in 15 ml polypropylene conical
tubes. Each assay contained 50 ml of the bacteria concen-
trate and 50 ml of the 1000/ml worm suspension in 2 ml
of S-medium. Unless specified, the final concentrations of
drugs in the media were 5 mg/ml 5-HT and 0.5 mg/ml
fluoxetine. The number of immobile animals was scored fol-
lowing incubation on a rocking platform at 20. The incuba-
tion time for fluoxetine assays was 24 hr unless indicated
otherwise. Animals remaining completely immobile for 10 sec
were recorded as paralyzed.WTandmutant strains were always
assayed in parallel and the difference in the percentage of
paralyzed WT and mutant animals was determined. Fluoxe-
tine sensitivities of strains grown and assayed in parallel were
compared.
In experiments described in Figure 2, a and c, worms were
incubated in 5 mg/ml 5-HT or 0.5 mg/ml fluoxetine in M9
without food for 30–60 min and were then either transferred
to NGM plates to recover or examined immediately.
Resistance to aldicarb-induced paralysis was assayed as
described (Nurrish et al. 1999). Briefly, 20 1-day-old adults
per strain were transferred onto a NGMplate containing 1mm
aldicarb, and the number of animals paralyzed on the plate
was scored at various time points. An animal was scored as
being paralyzed if no movement was detected after prodding
with a platinum wire. To assay the inhibition of aldicarb effects
by 5-HTand fluoxetine, animals were preincubated for 2 hr on
plates containing 5-HT (5mg/ml), fluoxetine (0.5mg/ml), or
no drug control, before being exposed to aldicarb.
Imaging analysis and quantification of GFP reporters:One-
day-old young adult hermaphrodites were examined, unless
specified otherwise. For evaluation of AChTgfp expression
level, images of the 9th and 10th ACh neurons along the
ventral nerve cord were captured at a fixed exposure time of
150ms to 100%UV level, and the fluorescence intensity over a
25 3 25-pixel area within a neuron was quantified, using
Adobe Photoshop 7.0 software. For evaluation of the abun-
dance of UNC-49TGFP, images along the ventral nerve cord
were captured at a fixed exposure time of 300 ms and the
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fluorescence intensity over a 50 3 5-mm area as illustrated in
Figure 3e was quantified using Image J software.
GLR-1TGFP was evaluated by counting the number of GFP
puncta along the ventral cord in live, genotype-blinded ani-
mals under the fluorescence scope.
[3H]Lysergic acid diethylamide (LSD) binding assays: The
SER-7b expression vector and the binding assays with the
membrane fraction of COS-7 cells expressing SER-7b have
been published (Hobson et al. 2003, 2006). Briefly, COS-7 cells
were transiently transfected with the SER-7b expression
construct for 48 hr. The transfected cells were harvested and
lysed, and the membrane fraction of the lysate was collected
after centrifugation. [3H]LSD saturation binding and inhibi-
tion of [3H]LSD binding by 5-HTand fluoxetine were assayed
in a 100-ml reaction volume in a well of 96-wellmicrotiter plates
at room temperature. For saturation binding, the membrane
extract containing 15 mg proteins was incubated for 1 hr in the
dark with various concentrations of [3H]LSD (1–50 nm) to
obtain Bmax and Kd values. To test the affinity of 5-HT and
fluoxetine to SER-7b, the membrane extract was incubated
with 10 nm [3H]LSD and various concentrations of 5-HT and
fluoxetine, determining the ability to replace [3H]LSD bind-
ing. For both saturation and inhibition binding assays, non-
specific bindings were evaluated by incubation of the reaction
mixture with a 1000-fold excess of unlabeled LSD. The
binding assays were terminated by filtration with GF/B filters
(Perkin-Elmer, Wellesley, MA) previously soaked with 0.3%
polyethleneimine. The filters were washed three times with
ice-cold TEM buffer and dried overnight, and the radioactivity
was quantified by liquid scintillation counting. The binding
data were analyzed by nonlinear regression analysis using
DeltaGraph (DeltaGraph Version 4.0; DeltaPoint, Chicago).
Statistics: Statistical analyses were performed using Minitab
12.1 (Minitab Inc., 1998). For comparisons between two test
groups, Student’s t-tests were carried out. Comparisons be-
tween more than two groups used ANOVA (one-way) followed
by a Tukey’s pairwisemulticomparison procedure. Results that
could not be normalized were tested with nonparametric
Mann–Whitney U-tests or Kruskal–Wallis tests.
RESULTS
Fluoxetine and mutations in mod-5/SERT eliminate
5-HT in specific neurons: In C. elegans 5-HT in specific
neurons can be precisely discerned by whole-mount
staining of the entire animal with antibodies raised
against 5-HT. In WT larvae 5-HT immunoreactivity can
be detected in four classes, a total of seven neurons in
the head region (Figure 1a): a pair of the NSM secretory
neurons, a pair of the ADF chemosensory neurons, and
a pair of the AIM and the single RIH interneurons. In
addition, 5-HT immunoreactivity can be detected in a
pair of the HSN motorneurons in adults (Figure 1b).
Mutants of the tryptophan hydroxylase gene tph-1
showed no discernible 5-HT immunoreactivity (Sze
et al. 2000), confirming the specificity of the antibodies
to 5-HT. During the process of characterizing tph-1
function, we found that a GFP reporter for the tph-1
gene (tph-1Tgfp) was expressed primarily only in the
NSM, the ADF, and the adult HSN neurons (Figure 1, e
and f) (Sze et al. 2000). Subsequently, it was reported
that another essential enzyme for 5-HT synthesis, the
bas-1 decarboxylase, was not expressed in RIH (Hare
and Loer 2004). One explanation for these results
could be less efficient expression of the transgenes in
the AIM and RIH neurons. Alternatively, AIMs and RIH
do not synthesize 5-HT. To distinguish between these
possibilities, we analyzed mutants of the sole SERT gene
mod-5. In both the mod-5(n3314) deletion and mod-
5(n822) opal mutants, we observed 5-HT immunoreac-
tivity in NSMs, ADFs, and adult HSNs but not in AIMs
and RIH (Figure 1c). We concluded that AIMs and RIH
use MOD-5/SERT to absorb extracellular 5-HT, but do
not synthesize it.
We therefore used 5-HT immunoreactivity in the AIM
andRIHneurons as ameasurement to assess the efficacy
of MOD-5/SERT inhibitors in C. elegans. In WTanimals
incubated for 4 hr on culture plates containing 0.5mg/ml
fluoxetine or 0.4 mg/ml imipramine, 5-HT immunore-
activity in AIMs and RIH was substantially reduced (data
not shown). 5-HT immunoreactivity in AIMs and RIH
became undetectable in most animals following 24-hr
drug treatments (Figure 1d). Relatively high drug con-
centrations are commonly used in experiments with
C. elegans because drugs are supplied in growth media
and only small amounts of a drug enter animals (Lewis
et al. 1980). It has been reported that in the CNS of
rodents and humans SERT is expressed in many neu-
rons that do not express the enzymes essential for 5-HT
biosynthesis (D’Amato et al. 1987; Hoffman et al. 1998;
Lebrand et al. 1998; Verney et al. 2002). Thus, in mam-
mals as well as in C. elegans there are two distinctive pop-
ulations of serotonergic neurons: neurons synthesizing
Figure 1.—Fluoxetine treatment and mutations in mod-5/
SERTabolish anti-5-HT immunoreactivity in the RIH and AIM
neurons. (a–d) Photomicrographs of animals stained with
anti-5-HT antibodies. To test the effects of MOD-5/SERT in-
hibitors, WT animals were incubated overnight on NGM
plates containing 0.5 mg/ml of fluoxetine (as shown) or
0.4 mg/ml of imipramine (not shown) before fixation for
staining. (e and f) Photomicrographs of WT animals express-
ing tph-1Tgfp. All the animals shown have anterior to the right.
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5-HT and neurons absorbing 5-HT from extracellular
space. Our results indicate that for those 5-HT–absorbing
neurons fluoxetine treatment may result in a reduction,
rather than an increase, in 5-HT signals. This intrigu-
ing finding prompted us to further investigate the effects
of SSRIs on neuronal functions regulated by 5-HT.
The conditions for fluoxetine to inhibit 5-HT immu-
noreactivity in the AIM and RIH neurons were used as
a guideline in studies described below.
A behavioral assay for genetic survey of fluoxetine
action in living animals: The locomotory control circuit
ofC. elegans affords a simple paradigm for delineation of
the genetic basis and molecular mechanisms of SSRIs
on 5-HT downstream targets in a defined neural circuit.
C. elegans locomotion is a reproducible behavior reflect-
ing integrated signaling of multiple neurotransmitters
and neuromodulators, including ACh, GABA, gluta-
mate, neuropeptides, dopamine, and 5-HT. In either
solid or liquidmedium, C. elegansmoves continuously in
a sinuous fashion. It has been well established that 5-HT
and fluoxetine inhibit locomotion (Choy and Thomas
1999; Nurrish et al. 1999). We reasoned, if we could
identify the genes and locomotory properties regulated
by 5-HT and fluoxetine, that may give us some clues to
the actions of fluoxetine on 5-HT downstream targets.
In this study, we monitored C. elegans locomotion in
liquid media because of the ease to recognize paralyzed
worms in liquid. When bathed in liquid media contain-
ing 5-HTor fluoxetine, C. elegans stoppedmoving within
1 hr and the paralyzed animals could resume locomo-
tion when they were immediately transferred to drug-
free media (Figure 2a). Fluoxetine-induced paralysis
was dose dependent (Figure 2b).
We next sought cellular markers correlating with
paralysis induced by 5-HT and fluoxetine. C. elegans
may become paralyzed either by hypercontraction of the
body-wall muscles due to excessive stimulatory signaling
or by hyperrelaxation due to a paucity of stimulatory
signaling (Reiner et al. 1995). To distinguish between
these possibilities and to compare the effect of 5-HTand
fluoxetine, we examined the body-wall muscle sarco-
meres in living animals using GFP-tagged myosin heavy
chain protein MYO-3 (MYO-3TGFP). In untreated an-
imals the muscle fibers were interdigitated, reflecting
a normal muscle contractile tone; however, in animals
exposed to either 5-HT or fluoxetine for ,1 hr the
sarcomeres were elongated and muscle fibers were
stretched apart, remaining parallel to each other and
giving a relaxed appearance (Figure 2c). By contrast,
animals treated with the cholinesterase inhibitor aldi-
carb, which causes hypercontraction of the body-wall
muscles, showed densely packed muscle fibers (Figure
2c). Interestingly, animals incubated in media contain-
ing 5-HT for 4 hr became adapted to the drug and
resumed muscle contractile tone, whereas the muscle
fibers in animals incubated with fluoxetine remained
relaxed (Figure 2c). Incidentally, animals exposed to
5-HT resumed locomotion, but animals exposed to flu-
oxetine remained paralyzed even after 24 hr and died.
These results suggest that both 5-HT and fluoxetine
caused profound body-wall muscle relaxation; however,
their actions are not identical.
To test whether paralysis induced by fluoxetine is
a result of inactivation of MOD-5/SERT, we analyzed
mod-5 mutants. The mod-5(n3314) and mod-5(n822) mu-
tants grown on NGM plates exhibited superficially nor-
mal locomotion, as previously reported (Ranganathan
et al. 2001). Both mutants remained sensitive to fluox-
etine in the paralysis assay, although their sensitivi-
ties were slightly reduced compared to WT animals
(Figure 2d). Furthermore, the tph-1(mg280) mutant
was fully sensitive to fluoxetine-induced paralysis (Fig-
ure 2d). These results are in agreement with a pub-
lished study (Ranganathan et al. 2001). MYO-3TGFP
in untreated mod-5 mutants was similar to that in WT
animals, although the muscle fibers in the untreated
tph-1 mutant were often thicker and more branching
(supporting information, Figure S1). Fluoxetine caused
muscle relaxation in both mod-5 and tph-1 mutants
(Figure S1).
To further characterize this fluoxetine assay, we tested
mutants of type II calcium- and calmodulin-dependent
protein kinase (CaMKII) unc-43. It has been reported
that unc-43 loss- and gain-of-function mutations cause,
respectively, hypo- and hypercontraction of the body-
wall muscles (Reiner et al. 1995, 1999). Indeed, the unc-
43(n498)g f mutant displayed densely packed MYO-3T
GFPmuscle fibers (Figure 2c). Fluoxetine did not cause
muscle relaxation in the unc-43gf mutant, although the
muscle fibers were packed less densely compared to
untreated unc-43gf animals (Figure 2c). The unc-43gf
mutant was more resistant, whereas the unc-43(n409)lf
mutant was hypersensitive to fluoxetine-induced paral-
ysis (Figure 2e). These results showed that the sensitivity
to fluoxetine-induced paralysis could be influenced by a
particular component in the locomotory system, sug-
gesting that this assay may allow us to identify additional
genes and functional pathways regulated by fluoxetine.
5-HT and fluoxetine regulate ACh, GABA, and
glutamate neurotransmission: To characterize the im-
pact of 5-HT and fluoxetine on synaptic transmission
of the locomotory circuit, we examined ACh, GABA,
and glutamate signaling in living C. elegans. We assayed
ACh release at the body-wall neural muscular junctions
(NMJs) by measuring the sensitivity to the acetylcho-
linesterase inhibitor aldicarb. Using GFP reporters,
we analyzed the expression of genes involved in ACh,
GABA, and glutamate neurotransmission and exam-
ined the morphology of the lomomotory neurons. We
also tested fluoxetine sensitivity in mutants of ACh,
GABA, and glutamate neurotransmission, using the
paralysis assay.
Aldicarb causes paralysis in C. elegans due to the
accumulation of ACh at the body-wall NMJs and is
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therefore frequently used to measure steady-state ACh
release in living animals (Mahoney et al. 2006). 5-HT
and fluoxetine reduced the paralytic effect of aldicarb
(Figure 3a), as previously reported (Nurrish et al.
1999). By contrast, 5-HT and fluoxetine did not inhibit
sensitivity to levamisole, a specific agonist of the
nicotinic ACh receptor UNC-29 in the body-wall
muscles (data not shown) (Nurrish et al. 1999),
suggesting that 5-HT regulates presynaptic ACh neuro-
transmission. We next examined a GFP reporter under
the control of a common promoter element shared by
the vesicular ACh transporter gene unc-17 and the cho-
line acetyltransferase gene cha-1 (AChTgfp) (Alfonso
et al. 1994). 5-HT and fluoxetine did not cause any dis-
cernible changes in the morphology of cholinergic
neurons, but they both reduced AChTgfp expression.
Following 2 hr exposure to either 5-HT or fluoxetine,
there was a modest 10% reduction in GFP fluorescence
in the ventral cord motorneurons, compared to age-
matched, untreated controls (Student’s t-test, P , 0.05
for 5-HT and P , 0.06 for fluoxetine, N = 30 per
treatment). Twenty-four hours of exposure to fluoxe-
tine resulted in an 30% reduction in AChTgfp in-
tensity (Figure 3b). Fluoxetine also reduced aldicarb
sensitivity and downregulated AChTgfp expression in
mod-5 mutants (Figure 3, a and b). These results
Figure 2.—Fluoxetine and 5-HTcause muscle relaxation. (a) The percentage of WTworms moving in M9 (open bar) and in M9
supplemented with 5 mg/ml 5-HT or 0.5 mg/ml fluoxetine (solid bars). The paralyzed animals resumed locomotion after they
were transferred to standard culture plates (shaded bars). Each bar represents the mean of three independent experiments, each
performed with three replicates 6 SEM. One-day-old adults were tested. (b) Dosage dependence of the paralytic effect of fluox-
etine in WT animals. Larval stage four (L4) worms were incubated for 24 hr in liquid media without fluoxetine or containing
fluoxetine at indicated concentrations. Each bar represents the mean of three independent experiments, each performed with
three replicates 6 SEM. Different letters represent a significant difference (one-way ANOVA, P, 0.05). (c) Visualization of body-
wall muscle sarcomeres in living C. elegans. WTanimals expressing an integrated MYO-3TGFP transgene were incubated for 30 min
or 4 hr in media without drug or supplemented with 5 mg/ml 5-HT, 0.5 mg/ml fluoxetine, or 0.8 mm aldicarb. One-day-old adults
were examined. (d and e) Quantification of fluoxetine-induced paralysis in WT and mutants. Fluoxetine sensitivity was scored by
calculating the percentage of worms paralyzed following 24-hr incubation in liquid media supplemented with 0.5 mg/ml fluoxetine.
The values of each mutant strain are normalized to that of WT worms assayed in parallel. Each bar represents the mean of three
independent experiments 6 SEM. *P , 0.05, **P ,0.01, Student’s t-test. In a and c, the assays were performed with animals in
culture media without food, allowing fast ingestion of the drugs, and thus likely reflecting the maximal speed of drug effects. In
b, d, e, and all other experiments described in this article the assays were performed with well-fed animals, reflecting optimal
physiological conditions.
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indicate that the drug treatments did not damage the
ACh neurons. Rather, both 5-HT and fluoxetine may
reduce ACh signaling at the body-wall NMJs and the
downregulation of cha-1 and unc-17 could account for
part of the fluoxetine effect; however, this action of
fluoxetine is independent of MOD-5/SERT.
Anunc-29 loss-of-functionmutant was hypersensitive to
fluoxetine-induced paralysis, although a cha-1 reduction-
Figure 3.—Action of flu-
oxetine and 5-HT on the
ACh, GABA, and glutamate
systems. (a) Aldicarb-induced
paralysis of animals pre-
treated with 5-HT or flu-
oxetine and without
pretreatment. Left, the per-
centage of worms paralyzed
after 60 min of exposure to
aldicarb. Right, the time
course of aldicarb-induced
paralysis. The error bars
indicate SEM (n . 3 rep-
licates). Different letters
represent a significance dif-
ference (one-way ANOVA,
P , 0.05). (b) Fluoxetine
downregulates AChTgfp
in WT and mod-5 mutant
animals. Left, photomicro-
graphs of AChTgfp expres-
sion in animals untreated
and treated with fluoxetine
(0.5 mg/ml, 24 hr). Right,
intensity of AChTgfp in
L4 animals without and
with fluoxetine treatment
was quantified by measur-
ing the fluorescence in
9th and 10th neurons from
the anterior (indicated in
the photomicrographs by
arrows) in individual ani-
mals. Each bar represents
three independent exper-
iments 6 SEM. ***P ,
0.001, Student’s t-test.
(c and d) Fluoxetine sen-
sitivity of ACh, GABA, and
glutamate mutants. Flu-
oxetine sensitivities were
measured as described in
Figure 2d. Each bar repre-
sents three independent
experiments 6 SEM. *P ,
0.05, **P , 0.01, ***P ,
0.001, compared to WT,
Student’s t-test. (e and f)
UNC-49TGFP expression
in WT animals treated with
5-HT and fluoxetine. (e)
Quantification of the fluo-
rescence within an area of
50 3 5 mm at the loco-
motory NMJs (as depicted in the photomicrograph). The average intensity in fluoxetine-treated animals is normalized to
that of untreated animals. The experiment was performed six times. The results represent one set of blinded experiments
(see Figure 6). *P , 0.05. (f) UNC-49TGFP was increased in the head region. Note that the fluorescence in animals treated with
fluoxetine was higher than that in those treated with 5-HT. In contrast, UNC-49TGFP was reduced following 2 hr of treatment
with 6 mm of the GABA agonist muscimol, which is consistent with ligand-induced internalization of GABAa receptor in mam-
malian systems (Kittler et al. 2002).
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of-function allele did not significantly alter fluoxetine
sensitivity (Figure 3c). The slo-1 BK potassium channel
gain-of-function allele ky399, which reduced ACh re-
lease (Davies et al. 2003), was hypersensitive to fluoxe-
tine in the paralysis assay (Figure 3d). Conversely, a slo-1
loss-of-function allele and a mutant of the negative ACh
neurotransmission regulator tom-1 both exhibited an
increase in ACh neurotransmission (Wang et al. 2001;
Gracheva et al. 2006) and were both more resistant to
fluoxetine as compared to WT (Figure 3d). These data
suggest a model in which 5-HT signaling inhibits ACh
neurotransmission and a deficit in ACh signaling may
facilitate muscle relaxation following 5-HT and fluoxe-
tine treatments.
We next examined GABAergic neurons. Since GABA
is the major inhibitory input to the body-wall muscles,
5-HT and fluoxetine could cause muscle relaxation by
increasing GABA signaling. 5-HTand fluoxetine did not
produce an appreciable change in the expression of a
GFP reporter for the GABA biosynthesis enzyme gluta-
mic acid decarboxylase unc-25 (data not shown). How-
ever, the GFP-tagged GABAa receptor protein UNC-49
(UNC-49TGFP) was significantly increased at the body-
wall NMJs (Figure 3e) and in the head muscles in
animals treated with 5-HT or fluoxetine, with the
fluorescence level higher in animals treated with fluoxe-
tine (Figure 3f). If increased UNC-49 activity were
responsible for the paralytic effect of fluoxetine, we
would expect unc-49 mutants to be more resistant to
fluoxetine. However, both unc-25 and unc-49 mutants
were hypersensitive to fluoxetine in the paralysis assay
(Figure 3c). Thus, the increase in UNC-49 expression
cannot account for paralysis induced by fluoxetine.
We also analyzed the relation of glutamate neuro-
transmission to fluoxetine sensitivity. Glutamate neuro-
transmission produces fast inhibitory inputs to the
locomotory circuit ( Jorgensen 2005). Glutamate re-
ceptors have been detected in the locomotory com-
mand interneurons and the motor neurons (Hart et al.
1995; Dent et al. 1997, 2000). Glutamate neurotrans-
mission is thought to function as a pattern generator by
regulating reciprocal inhibition between the forward
and the backward command neurons (Chalfie et al.
1985; Zheng et al. 1999; Brockie et al. 2001), and
excessive glutamate signaling may disrupt the neuronal
circuitry, resulting in a cessation of movement (Yates
et al. 2003). The eat-4 glutamate transporter is impli-
cated in glutamate neurotransmission (Lee et al. 1999;
Rand et al. 2000). The AMPA type glutamate receptor
glr-1 is the best-studied C. elegans GLR receptor: it is
expressed in the locomotory command interneurons
(Hart et al. 1995; Maricq et al. 1995) and controls
duration and direction of the movement (Zheng et al.
1999). We did not detect a significant change in the
expression and localization of the GFP-tagged EAT-4
protein (EAT-4TGFP) and GLR-1 protein (GLR-1TGFP)
in animals treated with 5-HT or fluoxetine (data not
shown, see below). But, mutants of eat-4 and glr-1 were
more resistant to fluoxetine-induced paralysis com-
pared to WT animals (Figure 3c).
Collectively, these experiments demonstrated a com-
plex of interactions between fluoxetine treatment and
synaptic functions of ACh, GABA, and glutamate. The
downregulation of AChTgfp and the upregulation of
UNC-49TGFP indicate that fluoxetine produces dis-
tinctive effects on different neurotransmitter systems.
5-HT receptors SER-7 and SER-5 antagonistcally
regulate fluoxetine sensitivity: While the common
effects of 5-HT and fluoxetine on MYO-3TGFP and
the neuronal markers were suggestive of fluoxetine
actions on 5-HT targets in the locomotory system, our
analyses of the mod-5 mutants showed that the fluoxe-
tine effects were largely independent of MOD-5/SERT
function (Figures 2d and 3, a and b). To gain more
insights into the molecular mechanisms by which fluox-
etine regulates synaptic functions and the relation to
5-HT, we took advantage of available deletion mutants
of predicted 5-HT receptors and tested their ability to
block fluoxetine-induced paralysis. None of tested 5-HT
receptormutants showed obvious defects in locomotion
per se. Sensitivity to fluoxetine-induced paralysis was
not significantly changed in mutants of mod-1 (two
alleles), ser-3 (three alleles), ser-4, T02E9, and C24A8.1
(data not shown). The ser-1(ok512) allele modestly
slowed down paralysis (Figure S2). By contrast, three
alleles of ser-7, which is most related to the mammalian
5-HT7 receptor (Hobson et al. 2006), were all signifi-
cantly resistant to fluoxetine-induced paralysis compared
to WT animals (Figure 4a, Figure S2). The ser-1;ser-7
double mutant did not show stronger resistance than
the ser-7 singlemutant, asmeasured after 40min (Figure
S2) and 24 hr (Student’s t-test, P = 0.13, n. 3 replicates)
of exposure to fluoxetine. Transgenic expression of the
WT ser-7 gene restored fluoxetine sensitivity of the ser-7
mutants (Figure 4a), indicating that SER-7 function
mediates this fluoxetine action. However, the ser-7
mutants were not completely resistant to fluoxetine-
induced paralysis, although all three ser-7 alleles are
deletion mutations predicted to be functional null
(Hobson et al. 2006). It is possible that fluoxetine could
influence other, SER-7-independent functions in the
locomotory circuit.
To determine whether SER-7 specifically mediates
fluoxetine action or is a target shared by SSRIs, we
analyzed two other SSRIs, sertraline (Zoloft) and
escitalopram (Lexapro, Cipralex). Both sertraline and
escitalopram induced paralysis inC. elegans, and the ser-7
mutants were more resistant than WT (Figure 4b).
In contrast to the ser-7 mutants, two ser-5 deletion
alleles both predicted to be functional null (Harris
et al. 2009) were both hypersensitive to fluoxetine-
induced paralysis compared to WT (Figure 4c). The
ser-5 mutants were also hypersensitive to inhibition of
locomotion by 5-HT (Figure S3). Interestingly, two trans-
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genic arrays of the WT ser-5 gene, Ex[ser-5(1)], not only
reversed the hypersensitivity of the ser-5mutant, but also
conferred resistance to fluoxetine in both ser-5 and WT
backgrounds (Figure 4, c and d). These results suggest
that SER-5 activity antagonizes the inhibitory effects of
fluoxetine.
We further tested genetic interaction between ser-7
and ser-5. The ser-5;ser-7 double mutant was more
resistant to fluoxetine compared to WT, although the
resistance was slightly weaker than that of the ser-7 single
mutant (Figure 4d). Overexpression of SER-5 further en-
hanced resistance to fluoxetine in ser-7 mutants (Figure
4d). Taken together, these results suggest that SER-5
signaling and SER-7 signaling antagonistically regulate
fluoxetine action on the locomotory circuit.
Mutations in ser-7 do not disrupt fluoxetine actions
on the ACh and GABA systems: We asked whether
SER-7 is required for fluoxetine to regulate synaptic
functions in the locomotory system. Two experimental
results indicate that the action of fluoxetine on ACh
neurotransmission is unaffected in the absence of SER-7
(Figure 5). First, fluoxetine inhibited aldicarb sensitivity
in the ser-7 mutants as in WT animals (Figure 5a).
Second, fluoxetine reduced AChTgfp expression in the
ser-7 mutants (Figure 5b).
SER-7 is also not required for fluoxetine action on
theGABA system (Figure 6). Fluoxetine increasedUNC-
49TGFP abundance in ser-7 mutants as in WT animals
(Figure 6a). Furthermore, if SER-7 acts in the GABA
signaling pathway, a double mutant of ser-7 and GABA
synthesis mutant unc-25 would be either hypersensitive
to fluoxetine as is the unc-25 mutant or resistant to flu-
oxetine as is the ser-7mutant. In contrast, we found that
the fluoxetine sensitivity of the ser-7; unc-25 double
mutant was in between that of the two single mutants
(Figure 6b). Collectively, the data suggest that SER-7
regulates the activity of the locomotory system via a
mechanism other than ACh and GABA.
SER-5 and SER-7 act in the same pathway as GLR-1
to regulate fluoxetine sensitivity: We also explored the
relation of SER-5 and SER-7 to glutamate neurotrans-
mission. GLR-1TGFP is expressed in puncta along the
axons of the locomotory command neurons extending
the full length of the ventral nerve cord, each punctum
corresponding to a single synapse, and the density of
GLR-1 synapses along the ventral cord is almost invari-
able between animal and animal (Rongo et al. 1998).
Although GFP intensity of individual puncta was not
significantly changed (data not shown), the number of
GLR-1TGFP synapses was reduced in ser-7 mutants,
compared to age-matched WT animals (Figure 7a).
To explore the functional relationship between glu-
tamate neurotransmission and ser-7, we generated
double mutants. Single mutants of ser-7, glr-1, and eat-4,
as well as double mutants of ser-7;glr-1 and ser-7;eat-4, all
exhibited similar resistance to fluoxetine (Figure 7b).
To test if glutamate signaling is a downstream target of
SER-7, we attempted to overexpress SER-7. Expressing
the ser-7(1) transgene in a WT background caused hy-
persensitivity to fluoxetine-induced paralysis (Figure 7b).
However, the glr-1 mutant expressing the same ser-7(1)
transgene was as resistant to fluoxetine as the glr-1
Figure 4.—SSRI-induced pa-
ralysis in ser-5 and ser-7 mutants.
Larval stage four (L4) worms were
incubated for 24 hr in liquid me-
dia supplemented with a drug:
0.5 mg/ml fluoxetine (a and d);
0.5 mg/ml fluoxetine, 0.25 mg/ml
sertraline, and 2.25 mg/ml escita-
lopram (b); and 0.25 mg/ml flu-
oxetine (c). Drug sensitivities
were calculated as described in
Figure 2d. The values of the mu-
tants are normalized to that of
WTassayed in parallel. Two trans-
genic lines each for Ex[ser-7(1)]
and Ex[ser-5(1)] were assayed.
Each bar represents at least three
independent experiments 6
SEM. *P , 0.05, **P , 0.01,
***P , 0.001, Student’s t-test.
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mutant (Figure 7b), suggesting that GLR-1 activity is
required for SER-7 to promote paralysis by fluoxetine.
Furthermore, the fluoxetine sensitivity of the ser-5;glr-1
double mutant was similar to that of the glr-1 single
mutant (Figure 7b), suggesting that the fluoxetine
hypersensitivity of the ser-5 mutants also depends on
GLR-1 function.
Fluoxetine binds to SER-7: We tested whether fluox-
etine directly binds SER-7 expressed heterologously in
mammalian COS-7 cells, using a standard approach
(Pert et al. 1973). One group of us previously estab-
lished that the membrane of COS-7 cells transiently
expressing the SER-7b isoform exhibits saturable spe-
cific binding to the 5-HT-like ligand [3H]LSD (Hobson
et al. 2003, 2006). 5-HT could efficiently displace
[3H]LSD binding, while dopamine, histamine, tyra-
mine, and octopamine did not show a significant affinity
to SER-7b (Hobson et al. 2003). Like 5-HT, fluoxetine
effectively competed [3H]LSD for binding SER-7b ex-
pressed in the COS-7 cells with IC50 of 0.42 6 0.03 mm
(Figure 8), suggesting that fluoxetine can directly bind
to SER-7.
DISCUSSION
SSRIs are useful in the treatment of a wide spectrum
of behavioral and psychiatric disorders. Increasingly it
has become clear that many of these disorders are
inheritable, with each involving multiple genetic loci
contributing small and additive effects to a complex of
symptomatic traits. While the action of SSRIs as SERT
inhibitors is well established, the cellular andmolecular
mechanisms by which SSRIs alleviate specific symptoms
are poorly understood. In this study, we identified two
additional aspects of fluoxetine action on the seroto-
nergic system through genetic analyses in C. elegans. We
showed that fluoxetine eliminated 5-HT in specific
neurons. These neurons absorb extracellular 5-HT via
MOD-5/SERT but do not synthesize it. Furthermore, we
demonstrated that fluoxetine directly targets G-protein–
coupled 5-HTreceptors to regulate a behavioral circuit.
These findings could shed some light on therapeutic
effects of fluoxetine and our understanding of 5-HT
neurotransmission.
The effects of fluoxetine are multifactoral: There is
an ongoing debate on the effects of SSRIs on 5-HT
signaling. In rodents, administration of fluoxetine im-
mediately induces a significant increase in the extracel-
lular levels of 5-HT in the brain (Schatzberg and
Nemeroff 2004). Intriguingly, a SERT knockout mouse
showed reduced brain 5-HT (Bengel et al. 1998).
Furthermore, an allele of reduced SERT expression is
found in patients suffering bipolar disorder and autism
(Bartlett et al. 2005; Brune et al. 2006; Barnett and
Smoller 2009). In this study, we identified twodistinctive
populations of serotonergic neurons in C. elegans: the
NSM, ADF, and HSN neurons producing 5-HT and the
RIHandAIMneurons absorbing 5-HT fromextracellular
space but unable to synthesize it. We showed that
fluoxetine and imipramine, like the mod-5/SERT muta-
tions, eliminated 5-HT in the AIM and RIH neurons.
5-HT–absorbing neurons are likely an evolutionary
conserved feature of the serotonergic system. In rodents
SERT is expressed in a range of CNS neurons that do not
express 5-HT biosynthesis enzymes (Gaspar et al. 2003).
In particular, SERT is expressed transiently in the thala-
mus and in all primary sensory areas including visual,
auditory, and somatosensory areas in early postnatal
rodents (D’Amato et al. 1987; Bengel et al. 1997;
Hansson et al. 1999) and in nonmonoaminergic neurons
indevelopinghumancerebral cortex (Verney et al. 2002).
How does blocking SERT function in 5-HT–absorbing
neurons possibly affect 5-HT signaling? One possible
Figure 5.—Action of fluoxetine and 5-HT on ACh in ser-7
mutants. (a) Aldicarb-induced immobility of animals pre-
treated with 5-HT (5 mg/ml) or fluoxetine (0.5 mg/ml) or
without pretreatment. The values of the mutants and pre-
treated animals are normalized to that of WTanimals without
pretreatment. (b) Fluoxetine downregulates AChTgfp in WT
and ser-7 mutant animals. Intensity of the fluorescence in the
9th and 10th neurons from the anterior (as shown in Figure
3b) was quantified. The values of WTanimals treated with flu-
oxetine (0.5 mg/ml, 24 hr) and the ser-7(tm1325) mutant un-
treated and treated with fluoxetine are normalized to that of
untreated WTassayed on the same day. Each bar represents at
least three replicate experiments 6 SEM. ***P , 0.001, Stu-
dent’s t-test.
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role of 5-HT–absorbing neurons could be to scavenge
5-HT spillover, thereby enhancing the specificity of the
signaling of 5-HT transmission. Indeed, the axons of the
AIM and RIH neurons are close to the axons of ADF and
NSM (White et al. 1986). This model is consistent with
published studies showing that mod-5/SERT-null mu-
tants exhibit certain behavioral phenotypes of increased
5-HT signaling (Ranganathan et al. 2001). However, it
is possible that 5-HT–absorbing neurons use 5-HT as
borrowed transmitter, serving as ‘‘relay stations’’ to pass
5-HT from the original neuronal sources to distant
targets. The support for this idea is the presence of the
vesicular monoamine transporter (VMAT) CAT-1 in the
AIM and RIH neurons (Duerr et al. 1999; Sze et al.
2002), indicating the capability to store imported 5-HT
in the synaptic vesicles. If this model is correct, that
would imply that fluoxetine reduces 5-HT singling
mediated by these neurons.
Our genetic and biochemical analyses indicate that
fluoxetine acts in part by targeting 5-HTreceptors. This
result is consistent with the biochemical studies showing
that fluoxetine and other SSRIs bind to many subtypes
of mammalian 5-HT receptors (Kroeze and Roth
1998). Interestingly, our data suggest that the actions
of fluoxetine and 5-HT are not identical. Fluoxetine
appeared to produce greater effects than exogenous
Figure 6.—Action of fluoxetine on GABA in
ser-7 mutants. (a) UNC-49TGFP expression in
ser-7 mutants. Intensity of the fluorescence along
the locomotory NMJs was quantified as described
in Figure 3e. The values of WT treated with flu-
oxetine (0.5 mg/ml, 2 hr) and ser-7(tm1325) ani-
mals untreated and treated with fluoxetine are
normalized to that of untreated WT. The exper-
iment was performed six times. These data repre-
sent one set of experiments with genotype and
treatment blinded. The number of animals ex-
amined: WT, 9 untreated and 10 treated with flu-
oxetine; ser-7, 12 untreated and 6 treated with
fluoxetine. *P, 0.05, Student’s t-test. (b) Fluoxetine-induced paralysis. Fluoxetine sensitivity was calculated as described in Figure
2d. Each bar represents three replicate experiments6 SEM. **P, 0.01, ***P, 0.001. There is no significant difference between
WT and ser-7; unc-25 (P . 0.9, Student’s t-tests).
Figure 7.—Genetic interaction between glr-1,
ser-5, and ser-7. (a) Quantification of GLR-1TGFP
puncta in WT and ser-7(tm1325) animals. GLR-
1TGFP is localized to the punctate structure
along the ventral nerve cord (Rongo et al.
1998). Individual GLR-1TGFP puncta in 1-day-
old adults, genotype blinded, were counted un-
der a fluorescence microscope, N = 15 per strain.
The P-value is indicated on the top of the bar
(Student’s t-test). (b) Fluoxetine-induced paraly-
sis. The percentage of paralyzed animals, normal-
ized to that of WT assayed on the same day, is
shown for the mutants and transgenic animals.
Each bar represents three replicate experiments6
SEM. The differences between glr-1 and ser-5;glr-1
and the differences between glr-1, ser-7;glr-1, and
glr-1;Ex[ser-7(1)] are not significant (P . 0.1, Stu-
dent’s t-test).
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5-HT on examined neuronal markers. Furthermore,
animals treated with serotonin but not with fluoxetine
could recover and resume locomotion. The recovery is
unlikely due to 5-HT being unstable (Figure S4),
suggesting animals can adapt to 5-TH but not to
fluoxetine. It will be interesting to define the binding
sites of 5-HT and SSRIs on SER-7 in the future.
It has been established that fluoxetine, but not 5-HT,
can induce C. elegans nose contraction, demonstrating
that fluoxetine can target genes outside of 5-HT signal-
ing pathways to regulate behavior (Choy and Thomas
1999; Choy et al. 2006).However, we found that the nrf-6
mutant, which is strongly resistant to fluoxetine-
induced nose contraction (Choy and Thomas 1999),
did not affect fluoxetine-induced paralysis (Figure 3c).
Thus, systematic characterization of fluoxetine effects
on individual behaviors in C. elegans may identify its
gene targets in 5-HT signaling pathways, as well as the
genes mediating other aspects of SSRI actions.
Interaction between 5-HT and other neurotransmit-
ters: Our analysis of GFP reporters revealed that
fluoxetine influences discrete steps of synaptic trans-
mission of ACh, GABA, and glutamate. Regulation of
synaptic function by 5-HT signaling is thought to play
myriad roles in the modulation of emotion, cognition,
and motor behavior in mammals (Millan 2003). In-
creased central cholinergic tone induces depression
in humans ( Janowsky and Overstreet 1990). Fluox-
etine is useful in the treatment of congenital myas-
thenic syndromes, which is characterized by increased
ACh neurotransmission at NMJs (Harper et al. 2003;
Colomer et al. 2006).
Our genetic analyses suggest that SER-5 and SER-7 act
antagonistically to regulate GLR-1 signaling in the
lomocotory circuit. Opposing 5-HTreceptors have been
found to modulate other behaviors in C. elegans. For
example, ser-7 and ser-1 stimulate egg laying in opposition
to ser-4 (Hapiak et al. 2009), and ser-1 and ser-4 antago-
nistically regulate aging (Murakami and Murakami
2007). However, SER-5 and SER-7 have not been de-
tected in neurons directly involved in locomotion
(Tsalik et al. 2003; Carre-Pierrat et al. 2006; Harris
et al. 2009) and ser-7 mutants do not exhibit defects in
GLR-1–mediated nose-touch response (data not shown).
It is likely that SER-7 and SER-5 are not required for
glutamate neurotransmission but act indirectly to in-
fluence its activity in the locomotory circuit. Inter-
estingly, fluoxetine, imipramine, and several other
antidepressants can increase AMPA receptor phosphor-
ylation in the mouse brain (Svenningsson et al. 2002,
2007; Du et al. 2007).
We showed that loss of ser-7 function did not block
fluoxetine action on ACh and GABA neurotransmission
in the locomotory circuit. It has been reported that the
G-protein–coupled 5-HT receptors SER-1 (Dernovici
et al. 2007) and SER-4 (Govorunova et al. 2010) are also
involved in the control of locomotion. ser-1 is predicted
to regulate the locomotory circuit indirectly through
interneurons (Dernovici et al. 2007). Therefore, in
C. elegans, as inmammals (Lucki 1992), 5-HT is probably
not required for behavior to occur. Rather it may act
via distinct 5-HT receptors in multiple cellular sites to
coordinate synaptic functions of behavioral circuits.
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FIGURE S1.—Photomicrographs of MYO-3::GFP in the body-wall muscle sarcomeres in mod-5 and tph-1 mutants. Animals 
were incubated for 60 min in S-medium containing 0.5 mg/ml fluoxetine and the drug-free controls. The inset in lower left panel 
shows branches crossing the muscle fibers, which were frequently observed in untreated tph-1 mutants, but not in WT and mod-5 
mutant animals. One-day old adults were examined. 
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FIGURE S2.—The time course of fluoxetine-induced paralysis. The assay has been performed multiple times, and the data 
from one experiment are presented. 
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FIGURE S3.—Effects of 5-HT treatment on locomotion in WT, ser-5 and ser-7 mutant animals. One-day old animals were 
transferred onto NGM plates supplemented with 5 mg/ml 5HT(hatched bars) or without 5-HT (black bars) for 15 min. The 
number of body bends of individual animals was scored by continuously monitoring individual animals for 20 seconds. In the 
presence of 5-HT, locomotion of ser-5 mutants was slower than that of WT (p < 0.05). However, the difference between WT and 
the ser-7 mutant animals is not significant (p > 0.05).  Student’s t-test.     
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FIGURE S4.—Analysis of 5-HT stability in solution. The stability of 5-HT in solution was evaluated by testing its ability to 
induce egg laying in WT animals. 5-HT was dissolved in M9 buffer to give the final concentration of 5 mg/ml 5HT, and the 
solution was stored in dark at 20oC. To test the response to 5-HT, animals were placed individually into wells of a 96-well plate, 
with each containing 100 ml of M9 buffer or M9 buffer containing 5-HT. The number of eggs laid was scored after 60 min. 
Animals did not laid egg in M9 buffer (data not shown) (Trent et al. 1983). There is no significant difference in the number of eggs 
laid between animals incubated in the solution at these four time points  (p > 0.4 Student’s t-test). 
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